Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216255 · ClinicalTrials.gov registry record · Phase 2
EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00216255: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00216255 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00216255, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
Interventions
- DRUG Placebo
- DRUG Pagoclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00216255
The ClinicalTrials.gov registry entry for NCT00216255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00216255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00216255 about?
NCT00216255 is a clinical study titled "EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study". The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
What is the current status of trial NCT00216255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00216255?
The interventions under investigation include: Placebo (DRUG), Pagoclone (DRUG).
Who is sponsoring clinical trial NCT00216255?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.